John is a 35-year-old male with moderately to severely active Crohn’s disease. He has been recently started on deucravacitinib 6 mg twice daily as part of a clinical trial. His current medications include mesalamine 2.4 g daily and low-dose prednisone 10 mg daily. He reports persistent abdominal pain and diarrhea despite therapy. He has no known drug allergies and is insured with moderate copayments. He expresses concern about the effectiveness of his new medication after 8 weeks of treatment.

Question: Based on the 12-week Phase 2 study results of deucravacitinib in Crohn’s disease, what is the most appropriate pharmacist counseling point regarding John’s expectations for clinical remission?

Maria is a 42-year-old female with moderately active ulcerative colitis who has been prescribed deucravacitinib 6 mg twice daily. She has a history of mild asthma and takes inhaled corticosteroids. She is concerned about potential side effects of her new medication and asks the pharmacist about its safety profile, especially compared to other immunomodulators she has used in the past.

Question: What is the most accurate statement regarding the safety of deucravacitinib in patients with ulcerative colitis based on recent Phase 2 trial data?

David is a 50-year-old male with moderate ulcerative colitis who is considering enrolling in a clinical trial for a new TYK2 inhibitor. He asks the pharmacist about the challenges of clinical trials in inflammatory bowel disease and how placebo effects might impact study outcomes.

Question: What key insight from the deucravacitinib Phase 2 trials should the pharmacist share with David regarding placebo response in IBD clinical studies?